Image Analysis Group (IAG), a leading expert in clinical trial imaging and AI-driven biomarkers, has expanded its footprint in the United States by opening a new office in Cambridge, Massachusetts. This strategic move brings the company closer to the biotechnology and pharmaceutical hubs in the Boston area, enhancing its ability to form partnerships and offer local support for regional clinical trials.
The Cambridge office is set to bolster IAG’s capabilities across various therapeutic sectors, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. By establishing a presence in this life-sciences-rich ecosystem, IAG aims to work more effectively with sponsors and contract research organizations involved in Phase I–III clinical trials and imaging-intensive development programs. The company also anticipates creating new job opportunities in clinical imaging operations, data science, regulatory support, and business development over the next one to two years.
IAG’s new location will facilitate its comprehensive imaging services, which include clinical trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery. By embedding itself within the Boston life-sciences community, IAG expects to enhance collaborative efforts with biotechnology companies, pharmaceutical organizations, academic institutions, and clinical research centers.
With a global reach extending across North America, Europe, and the Asia-Pacific, IAG partners with pharmaceutical, biotechnology, and medical technology companies, as well as contract research organizations, on multi-center studies. The company’s international operations focus on delivering standardized imaging protocols, centralized data harmonization, and consistent imaging analysis across global trials.
Founded in 2007 and headquartered in London, IAG operates as an imaging Clinical Research Organization (iCRO). It supports pharmaceutical, biotechnology, and medical technology companies by providing imaging-based clinical trial endpoints. IAG’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight, serving areas including oncology, inflammatory disease, musculoskeletal, cardiometabolic, and rare disease indications.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.